// App-Quantinova.ai

426 : Management of fibroblast growth factor receptor inhibitor (FGFRi) treatment-emergent adverse events (TEAEs) of interest in patients (Pts) with locally advanced or metastatic urothelial carcinoma (mUC).

Researchers

Presenter

  • Arlene O. Siefker-Radtke

Principal Investigators

  • Se Hoon Park

  • Jess Garca-Donas

  • Robert A Huddart

  • Earle F Burgess

  • Mark T. Fleming

  • Arash Rezazadeh

  • Begona Mellado

  • Sergei Varlamov

  • Monika Joshi

  • Ignacio Duran

  • Scott T. Tagawa

  • Yousef Zakharia

  • Keqin Qi

  • Manish Monga

  • Manu Sondhi

  • Anne OHagan

  • Yohann Loriot

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Division of Hematology-Oncology, Samsung Medical Center, Department of Medicine, Seoul, South Korea

  • Fundacion Hospital de Madrid, Madrid, Spain

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Levine Cancer Institute, Charlotte, SC

  • Virginia Oncology Associates, US Oncology Research, Norfolk, VA

  • Norton Health Care, Louisville, KY

  • Servei d'Hematologia, Hospital Clinic de Barcelona, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

  • Altai Regional Cancer Center, Barnaul, Russia

  • Penn State Cancer Institute, Hershey, PA

  • Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain

  • Weill Cornell Medical College, New York, NY

  • University of Iowa, Iowa City, IA

  • Janssen Research and Development, Titusville, NJ

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research and Development, LLC, Spring House, PA

  • Department of Cancer Medicine, Institut Gustave Roussy, Paris-Sud University, Villejuif, France

Locations

  • United States

  • Italy

  • Republic of South Korea

  • Spain

  • United Kingdom

  • Russia

  • France

Companies

  • JB Medical Ltd.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Cisplatin

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • NCT02365597

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved